These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 21029840)
21. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Betteridge DJ; Gibson JM; Sager PT Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365 [TBL] [Abstract][Full Text] [Related]
23. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G; Maggioni AP Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394 [TBL] [Abstract][Full Text] [Related]
24. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Bruckert E; Giral P; Tellier P Circulation; 2003 Jul; 107(25):3124-8. PubMed ID: 12835406 [No Abstract] [Full Text] [Related]
26. Stricter cholesterol guidelines broaden indications for the 'statin' drugs. Capriotti T Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600 [No Abstract] [Full Text] [Related]
27. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly]. MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640 [No Abstract] [Full Text] [Related]
28. Rosuvastatin in patients with elevated C-reactive protein. Jenny-Avital ER N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275 [No Abstract] [Full Text] [Related]
29. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Robinson JG; Stone NJ Am J Cardiol; 2006 Nov; 98(10):1405-8. PubMed ID: 17134640 [TBL] [Abstract][Full Text] [Related]
30. JUPITER study highlights C-reactive protein as a cardiac risk factor. Cardiovasc J Afr; 2009; 20(2):146. PubMed ID: 19421655 [No Abstract] [Full Text] [Related]
31. How Common Is Residual Inflammatory Risk? Ridker PM Circ Res; 2017 Feb; 120(4):617-619. PubMed ID: 28209792 [No Abstract] [Full Text] [Related]
32. C-reactive protein levels and outcomes after statin therapy. Jaber BL; Madias NE N Engl J Med; 2005 Apr; 352(15):1603-5; author reply 1603-5. PubMed ID: 15832451 [No Abstract] [Full Text] [Related]
33. [Atherosclerosis from the point of view of hypothesis to evidence based medicine]. Yamada N Nihon Rinsho; 2011 Jan; 69(1):7-12. PubMed ID: 21226252 [TBL] [Abstract][Full Text] [Related]
34. Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed. Perez A; Bartholomew JR Cleve Clin J Med; 2010 Mar; 77(3):191-4. PubMed ID: 20200169 [TBL] [Abstract][Full Text] [Related]